Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 5,695 | 858 | 4,772 |
| Samples | 1,112 | 254 | 845 |
| Peptides | 964 | 180 | 786 |
Function
PTPN13 · Protein tyrosine phosphatase non-receptor type 13
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP is a large intracellular protein. It has a catalytic PTP domain at its C-terminus and two major structural domains: a region with five PDZ domains and a FERM domain that binds to plasma membrane and cytoskeletal elements. This PTP was found to interact with, and dephosphorylate, Fas receptor and IkappaBalpha through the PDZ domains. This suggests it has a role in Fas mediated programmed cell death. This PTP was also shown to interact with GTPase-activating protein, and thus may function as a regulator of Rho signaling pathways. Four alternatively spliced transcript variants, which encode distinct proteins, have been reported. [provided by RefSeq, Oct 2008].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 938 amino-acid changes on canonical ENST00000411767 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PTPN13 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PTPN13 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Endometrial Carcinoma | 13/42 31% | 41/612 7% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Glioblastoma | 7/98 7% | 0/0 0% |
| Hodgkins Lymphoma | 5/16 31% | 4/122 3% |
| Melanoma | 11/210 5% | 109/1899 6% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 7/133 5% |
| Unknown | 0/10 0% | 2/29 7% |
| Colorectal Carcinoma | 33/143 23% | 122/3239 4% |
| Gastric Carcinoma | 11/74 15% | 70/1809 4% |
| Cervical Carcinoma | 2/35 6% | 17/422 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Bladder Carcinoma | 7/58 12% | 28/956 3% |
| Non-Small Cell Lung Carcinoma | 33/304 11% | 25/1390 2% |
| Neuroendocrine Tumour | 14/154 9% | 9/577 2% |
| Other Solid Cancers | 2/94 2% | 44/1515 3% |
| Esophageal Carcinoma | 2/23 9% | 19/769 2% |
| Mesothelioma | 5/62 8% | 1/165 1% |
| Hepatocellular Carcinoma | 3/46 7% | 55/2210 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 16/810 2% |
| Ovarian Carcinoma | 10/109 9% | 15/998 2% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Burkitts Lymphoma | 5/32 16% | 0/196 0% |
| Non-Cancerous | 3/104 3% | 17/830 2% |
| Breast Carcinoma | 18/144 12% | 54/3264 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 15/752 2% |
| Rhabdomyosarcoma | 2/33 6% | 2/171 1% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
Mutation Distribution
Where PTPN13 is mutated · all tissues, split by cell line vs tissue
How many mutations in PTPN13 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 5,695 mutations in PTPN13
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|